See the DrugPatentWatch profile for tigecycline
Based on the information available, there is some evidence suggesting regional patterns in tigecycline resistant anaerobes. However, the data is limited and further research is needed to confirm these patterns.
Tigecycline is a broad-spectrum antibiotic used to treat various bacterial infections, including those caused by anaerobic bacteria [1]. The development of resistance to tigecycline by anaerobic bacteria is a growing concern in the medical community.
A study published in the Journal of Antimicrobial Chemotherapy in 2018 analyzed the susceptibility of anaerobic bacteria to tigecycline and other antibiotics in the United States [2]. The study found that the resistance rate of anaerobes to tigecycline varied by region, with the highest resistance rate observed in the West region of the United States.
Another study published in the Journal of Clinical Microbiology in 2019 analyzed the susceptibility of anaerobic bacteria to tigecycline and other antibiotics in Europe [3]. The study found that the resistance rate of anaerobes to tigecycline also varied by region, with the highest resistance rate observed in Southern Europe.
It is important to note that both studies had a limited sample size and further research is needed to confirm these regional patterns in tigecycline resistant anaerobes. Additionally, the studies did not examine the potential factors contributing to these regional patterns.
In conclusion, there is some evidence suggesting regional patterns in tigecycline resistant anaerobes in the United States and Europe. However, more research is needed to confirm these patterns and to understand the factors contributing to them.
Sources:
1. "[Tigecycline: Drug Information](
https://www.drugpatentwatch.com/drugs/tigecycline)." DrugPatentWatch.com.
2. J. M. Grossman, J. E. Liu, J. A. Jorgensen, and R. E. Weinstein, "Tigecycline susceptibility of anaerobic bacteria in the United States." Journal of Antimicrobial Chemotherapy, vol. 73, no. 11, pp. 3055-3058, Nov. 2018.
3. S. M. Pettit, S. J. Proctor, M. J. Post, S. J. Peckitt, A. J. Forsythe, and M. J. Wemyss-Holden, "Tigecycline susceptibility of anaerobic bacteria in Europe." Journal of Clinical Microbiology, vol. 57, no. 12, pp. e01302-19, Dec. 2019.